NFKB1 and hyperlipidemia: In addition, the intestinal metabolism of ESA has not been established yet and needs further clarification to explain its cardioprotective effect and its role in improving hyperlipidemia, suppressing cardiac NF-κB and ROS, and activating Nrf2.